India Glycols Ltd
- Market Cap ₹ 7,681 Cr.
- Current Price ₹ 1,147
- High / Low ₹ 1,223 / 792
- Stock P/E 26.3
- Book Value ₹ 438
- Dividend Yield 0.65 %
- ROCE 12.4 %
- ROE 11.3 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 2.62 times its book value
- Company has a low return on equity of 10.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,579 | 2,324 | 2,500 | 3,034 | 3,357 | 2,735 | 2,317 | 2,868 | 2,651 | 3,294 | 3,768 | 4,211 | |
| 2,455 | 2,149 | 2,263 | 2,712 | 2,941 | 2,433 | 2,026 | 2,599 | 2,346 | 2,879 | 3,257 | 3,562 | |
| Operating Profit | 124 | 175 | 237 | 322 | 416 | 303 | 291 | 269 | 305 | 415 | 511 | 649 |
| OPM % | 4.8% | 8% | 9% | 11% | 12% | 11% | 13% | 9% | 12% | 13% | 14% | 15% |
| -16 | -47 | 7 | 23 | 17 | 24 | 15 | 260 | 54 | 30 | 61 | 50 | |
| Interest | 163 | 139 | 127 | 125 | 143 | 97 | 83 | 70 | 100 | 121 | 164 | 167 |
| Depreciation | 89 | 69 | 72 | 73 | 76 | 78 | 80 | 80 | 94 | 101 | 115 | 155 |
| Profit before tax | -144 | -81 | 45 | 147 | 213 | 153 | 143 | 379 | 165 | 223 | 292 | 377 |
| Tax % | -38% | -30% | 22% | 34% | 38% | 25% | 8% | 10% | 15% | 23% | 21% | 22% |
| -89 | -57 | 35 | 97 | 133 | 115 | 132 | 340 | 141 | 173 | 231 | 293 | |
| EPS in Rs | -14.32 | -9.18 | 5.66 | 15.59 | 21.42 | 18.52 | 21.26 | 54.90 | 20.21 | 27.95 | 37.31 | 43.68 |
| Dividend Payout % | 0% | 0% | 9% | 13% | 14% | 16% | 14% | 7% | 19% | 14% | 13% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 17% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 74% |
| 5 Years: | 14% |
| 3 Years: | 39% |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 37% |
| 5 Years: | 27% |
| 3 Years: | 55% |
| 1 Year: | 34% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 34 |
| Reserves | 266 | 687 | 721 | 814 | 932 | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,899 |
| 2,264 | 1,236 | 1,095 | 834 | 1,000 | 999 | 1,137 | 1,047 | 1,112 | 1,348 | 1,892 | 1,691 | |
| 593 | 1,665 | 1,645 | 1,742 | 1,821 | 2,053 | 1,814 | 1,792 | 1,845 | 2,218 | 2,029 | 1,900 | |
| Total Liabilities | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
| 1,146 | 2,029 | 2,111 | 2,156 | 2,173 | 2,228 | 2,193 | 2,318 | 2,717 | 3,205 | 3,829 | 4,554 | |
| CWIP | 162 | 181 | 91 | 89 | 137 | 172 | 126 | 243 | 125 | 84 | 98 | 37 |
| Investments | 4 | 28 | 25 | 24 | 21 | 26 | 27 | 336 | 318 | 335 | 381 | 389 |
| 1,843 | 1,382 | 1,265 | 1,152 | 1,453 | 1,660 | 1,774 | 1,734 | 1,698 | 1,993 | 1,867 | 1,543 | |
| Total Assets | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -171 | 1,231 | 302 | 502 | 147 | 343 | 137 | 116 | 326 | 439 | 362 | 769 | |
| 175 | -78 | -40 | -103 | -128 | -151 | -148 | 76 | -330 | -503 | -736 | -767 | |
| -4 | -1,168 | -263 | -399 | 3 | -216 | 11 | -189 | -1 | 90 | 354 | 23 | |
| Net Cash Flow | -0 | -15 | -1 | -0 | 22 | -23 | -0 | 4 | -5 | 25 | -20 | 25 |
| Free Cash Flow | -53 | 1,137 | 260 | 373 | 9 | 193 | -11 | -264 | -109 | -103 | -391 | -47 |
| CFO/OP | -136% | 705% | 127% | 156% | 37% | 127% | 53% | 51% | 123% | 108% | 75% | 122% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 57 | 57 | 40 | 35 | 76 | 57 | 51 | 59 | 43 | 35 | 30 |
| Inventory Days | 109 | 128 | 129 | 87 | 124 | 146 | 166 | 148 | 209 | 224 | 209 | 139 |
| Days Payable | 55 | 120 | 144 | 152 | 143 | 155 | 158 | 137 | 209 | 222 | 175 | 123 |
| Cash Conversion Cycle | 115 | 66 | 42 | -25 | 17 | 67 | 65 | 62 | 60 | 44 | 70 | 47 |
| Working Capital Days | -110 | -94 | -117 | -78 | -50 | -64 | -79 | -31 | -46 | -63 | -56 | -49 |
| ROCE % | 3% | 5% | 9% | 15% | 20% | 14% | 10% | 9% | 8% | 11% | 12% | 12% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Potable Spirits Revenue Mix % of Net Revenue |
|
|||||||||
| BSPC Revenue Mix % of Net Revenue |
||||||||||
| Ethanol Blending Rate in India % ・Standalone data |
||||||||||
| Ethanol Distillation Capacity KLPD |
||||||||||
| Number of Countries Exported To count |
||||||||||
| Bio-Fuel Revenue Mix % of Net Revenue |
||||||||||
| IMFL Share of Potable Spirits Revenue % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
2h - Akshay Bansal moved to Ennature Bio Pharma; appointed Additional Executive Director and KMP for 5 years from July 31, 2026.
-
Material Update In Connection With Ennature Bio Pharma Limited With Reference To Observation Letter No. NSE/LIST/48932 Dated 17Th November, 2025 And No. DCS/AMAL/TS/R37/3905/2025-26 Dated 19Th November, 2025 ("Observation Letters"), Issued By The National Stock Exchange Of India Limited And BSE Limited (Collectively The "Stock Exchanges"), Respectively, Received In Relation To The Scheme Of Arrangement.
2h - Akshay Bansal transferred to Ennature Bio Pharma on 30 July 2026; appointed Additional Director and KMP from 31 July 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Jul
-
Communication To Shareholders - Intimation Of Web-Link Of The Annual Report For FY 2025-26
25 Jul - India Glycols sends FY 2025-26 annual report link; 42nd AGM on 19 August 2026.
-
Business Responsibility and Sustainability Reporting (BRSR)
24 Jul - India Glycols submitted its FY2025-26 BRSR as part of the annual report.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
Concalls
-
Jun 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT REC
-
Feb 2023Transcript PPT REC
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT REC
-
Aug 2022Transcript PPT REC
-
Jun 2022Transcript PPT REC
-
Feb 2022Transcript PPT REC
-
Nov 2021Transcript PPT REC
-
Aug 2021Transcript PPT REC
Business Segments [1]